Literature DB >> 19825447

Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.

Deborah A Thomas1, Susan O'Brien, Hagop M Kantarjian.   

Abstract

Significant advances have been achieved in the treatment of acute lymphoblastic leukemia (ALL) with the incorporation of targeted therapy agents. Targeting leukemia surface antigens with monoclonal antibodies is another promising strategy. This article comprehensively reviews available data regarding the use of rituximab for the treatment of Burkitt-type leukemia/lymphoma and CD20-positive precursor B-cell ALL. The incorporation of rituximab into frontline chemotherapy regimens for Burkitt-type leukemia/lymphoma appears to improve outcome. Preliminary data regarding the use of rituximab in frontline therapy for CD20- positive precursor B-cell ALL suggest its use may also be beneficial, particularly for the younger subsets.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19825447      PMCID： PMC4458386          DOI： 10.1016/j.hoc.2009.07.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  82 in total

1.  The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

Authors:  Jessica L Teeling; Wendy J M Mackus; Luus J J M Wiegman; Jeroen H N van den Brakel; Stephen A Beers; Ruth R French; Tom van Meerten; Saskia Ebeling; Tom Vink; Jerry W Slootstra; Paul W H I Parren; Martin J Glennie; Jan G J van de Winkel
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

2.  Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.

Authors:  P Feugier; A Van Hoof; C Sebban; P Solal-Celigny; R Bouabdallah; C Fermé; B Christian; E Lepage; H Tilly; F Morschhauser; P Gaulard; G Salles; A Bosly; C Gisselbrecht; F Reyes; B Coiffier
Journal:  J Clin Oncol       Date:  2005-05-02       Impact factor: 44.544

3.  Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.

Authors:  M J Borowitz; J Shuster; A J Carroll; M Nash; A T Look; B Camitta; D Mahoney; S J Lauer; D J Pullen
Journal:  Blood       Date:  1997-06-01       Impact factor: 22.113

4.  High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.

Authors:  Albert Oriol; Josep-Maria Ribera; Juan Bergua; Eduardo Giménez Mesa; Carlos Grande; Jordi Esteve; Salut Brunet; Maria-Jose Moreno; Lourdes Escoda; Jesus-Maria Hernandez-Rivas; Dieter Hoelzer
Journal:  Cancer       Date:  2008-07-01       Impact factor: 6.860

5.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.

Authors:  Taghi Manshouri; Kim-anh Do; Xuemei Wang; Francis J Giles; Susan M O'Brien; Helen Saffer; Deborah Thomas; Iman Jilani; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Journal:  Blood       Date:  2002-11-21       Impact factor: 22.113

Review 6.  GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas.

Authors:  Stephen J Schuster; Parameswaran Venugopal; Julie C Kern; Peter McLaughlin
Journal:  Leuk Lymphoma       Date:  2008-09

7.  A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial).

Authors:  Graham M Mead; Sharon L Barrans; Wendi Qian; Jan Walewski; John A Radford; Max Wolf; Simon M Clawson; Sally P Stenning; Claire L Yule; Andrew S Jack
Journal:  Blood       Date:  2008-07-08       Impact factor: 22.113

8.  Incorporating the use of GM-CSF in the treatment of chronic lymphocytic leukemia.

Authors:  Alessandra Ferrajoli
Journal:  Leuk Lymphoma       Date:  2009-03

Review 9.  The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence.

Authors:  Dina Attias; Sheila Weitzman
Journal:  Curr Opin Pediatr       Date:  2008-02       Impact factor: 2.856

10.  Permeability of human brain tumor to 99mTc-gluco-heptonate and 99mTc-albumin. Implications for monoclonal antibody therapy.

Authors:  E A Neuwelt; H D Specht; S A Hill
Journal:  J Neurosurg       Date:  1986-08       Impact factor: 5.115
View more
  15 in total

1.  Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.

Authors:  Deborah Thomas; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Elias Jabbour; Sherry Pierce; Jorge Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2010-10-01       Impact factor: 6.860

Review 2.  Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia.

Authors:  Hagop Kantarjian; Deborah Thomas; Alan S Wayne; Susan O'Brien
Journal:  J Clin Oncol       Date:  2012-08-13       Impact factor: 44.544

Review 3.  Progress in adult ALL: incorporation of new agents to frontline treatment.

Authors:  Jessica Leonard; Wendy Stock
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.

Authors:  Sarwish Rafiq; Anthony Siadak; Jonathan P Butchar; Carolyn Cheney; Gerard Lozanski; Naduparambil K Jacob; Rosa Lapalombella; Jackie McGourty; Meghan Moledor; Richard Lowe; Ben Setter; Jeffrey Jones; Joseph M Flynn; Leslie Andritsos; Steven Devine; Xiaokui Mo; David Jarjoura; Susheela Tridandapani; Paul Algate; John C Byrd; Natarajan Muthusamy
Journal:  MAbs       Date:  2013-06-07       Impact factor: 5.857

5.  Bevacizumab potentiates chemotherapeutic effect on T-leukemia/lymphoma cells by direct action on tumor endothelial cells.

Authors:  Li Wang; Wen-Yu Shi; Fan Yang; Wei Tang; Guillaume Gapihan; Mariana Varna; Zhi-Xiang Shen; Sai-Juan Chen; Christophe Leboeuf; Anne Janin; Wei-Li Zhao
Journal:  Haematologica       Date:  2011-02-17       Impact factor: 9.941

6.  Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Authors:  Michaela Liedtke; Clare J Twist; Bruno C Medeiros; Jason R Gotlib; Caroline Berube; Marcia M Bieber; Neelima M Bhat; Nelson N Teng; Steven E Coutre
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

7.  Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William Wierda; Farhad Ravandi; Srdan Verstovsek; Jeffrey L Jorgensen; Carlos Bueso-Ramos; Michael Andreeff; Sherry Pierce; Rebecca Garris; Michael J Keating; Jorge Cortes; Hagop M Kantarjian
Journal:  J Clin Oncol       Date:  2010-07-26       Impact factor: 44.544

Review 8.  Novel Therapies in Acute Lymphoblastic Leukemia.

Authors:  Kathleen W Phelan; Anjali S Advani
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

Review 9.  Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.

Authors:  Naval Daver; Susan O'Brien
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

10.  Rituximab added to standard chemotherapy and its effect on minimal residual disease during induction in CD20 positive pediatric acute lymphoblastic leukemia: a pilot RCT.

Authors:  Aditya Kumar Gupta; Anita Chopra; Jagdish Prasad Meena; Jay Singh; Ravindra Mohan Pandey; Sameer Bakhshi; Rachna Seth
Journal:  Am J Blood Res       Date:  2021-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.